Shield Therapeutics plc (LON:STX – Get Free Report)’s share price shot up 11.3% during mid-day trading on Thursday . The company traded as high as GBX 2.70 ($0.03) and last traded at GBX 2.70 ($0.03). 5,886,581 shares were traded during trading, an increase of 143% from the average session volume of 2,422,151 shares. The stock had previously closed at GBX 2.43 ($0.03).
Shield Therapeutics Stock Up 6.8 %
The company’s fifty day simple moving average is GBX 2.70 and its 200 day simple moving average is GBX 3.24. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50. The firm has a market capitalization of £23.46 million, a P/E ratio of -75.00 and a beta of 1.42.
Shield Therapeutics Company Profile
Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.
Further Reading
- Five stocks we like better than Shield Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- What is the Australian Securities Exchange (ASX)
- 3 Buy-and-Hold Stocks for Long-Term Growth
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
